查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1459812

溶瘤病毒免疫治疗市场 - 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 182 Pages | 商品交期: 2-10个工作天内

价格

溶瘤病毒免疫治疗市场 - 报告范围

TMR 关于全球溶瘤病毒免疫疗法市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球溶瘤病毒免疫疗法的收入2017-2031年期间的市场，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球溶瘤病毒免疫治疗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解溶瘤病毒免疫治疗市场。

市场概况
2022年市场价​​值 1.102 亿美元
2031 年市场价值 5.722 亿美元
CAGR 21.1%

该报告深入探讨了全球溶瘤病毒免疫疗法市场的竞争格局。全球溶瘤病毒免疫治疗市场的主要参与者已被确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球溶瘤病毒免疫治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按类型，2017-2031
    • 单纯疱疹病毒
    • 痘苗病毒
    • 腺病毒
    • 呼肠孤病毒
    • 其他的
  • 市场吸引力分析：按类型

第 7 章：全球市场分析与预测：按给药途径

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2017-2031
    • 瘤内
    • 静脉
  • 市场吸引力分析：按给药途径

第 8 章：全球市场分析与预测：按应用分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依应用分类，2017-2031
    • 黑色素瘤
    • 非小细胞肺癌（NSCLC）
    • 胰腺癌
    • 乳癌
    • 其他的
  • 市场吸引力分析：按给药途径

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Amgen Inc.
    • Merck & Co., Inc. (Viralytics Limited)
    • Shanghai Sunway Biotech Co., Ltd.
    • TILT Biotherapeutics
    • Oncorus, Inc.
    • Replimune Group, Inc.
    • Oncolys Biopharma, Inc.
    • Sorrento Therapeutics, Inc.
    • Oncolytics Biotech, Inc.
    • SillaJen, Inc.
Product Code: TMRGL44931

Oncolytic Virus Immunotherapy Market - Scope of Report

TMR's report on the global oncolytic virus immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oncolytic virus immunotherapy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the oncolytic virus immunotherapy market.

Market Snapshot
Market Value in 2022US$ 110.2 Mn
Market Value in 2031US$ 572.2 Mn
CAGR21.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oncolytic virus immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oncolytic virus immunotherapy market.

The report delves into the competitive landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oncolytic virus immunotherapy market profiled in this report.

Key Questions Answered in Global oncolytic virus immunotherapy Market Report:

  • What is the sales/revenue generated by oncolytic virus immunotherapy across all regions during the forecast period?
  • What are the opportunities in the global oncolytic virus immunotherapy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Oncolytic Virus Immunotherapy Market - Research Objectives and Research Approach

The comprehensive report on the global oncolytic virus immunotherapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oncolytic virus immunotherapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oncolytic virus immunotherapy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Herpes Simplex Virus
    • 6.3.2. Vaccinia Virus
    • 6.3.3. Adenovirus
    • 6.3.4. Reovirus
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Intratumoral
    • 7.3.2. Intravenous
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Melanoma
    • 8.3.2. Non-small Cell Lung Cancer (NSCLC)
    • 8.3.3. Pancreatic Cancer
    • 8.3.4. Breast Cancer
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2017-2031
    • 10.3.1. Herpes Simplex Virus
    • 10.3.2. Vaccinia Virus
    • 10.3.3. Adenovirus
    • 10.3.4. Reovirus
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Intratumoral
    • 10.4.2. Intravenous
  • 10.5. Market Value Forecast, by Application, 2017-2031
    • 10.5.1. Melanoma
    • 10.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 10.5.3. Pancreatic Cancer
    • 10.5.4. Breast Cancer
    • 10.5.5. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Route of Administration
    • 10.7.3. By Application
    • 10.7.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2017-2031
    • 11.3.1. Herpes Simplex Virus
    • 11.3.2. Vaccinia Virus
    • 11.3.3. Adenovirus
    • 11.3.4. Reovirus
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Intratumoral
    • 11.4.2. Intravenous
  • 11.5. Market Value Forecast, by Application, 2017-2031
    • 11.5.1. Melanoma
    • 11.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 11.5.3. Pancreatic Cancer
    • 11.5.4. Breast Cancer
    • 11.5.5. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2017-2031
    • 12.3.1. Herpes Simplex Virus
    • 12.3.2. Vaccinia Virus
    • 12.3.3. Adenovirus
    • 12.3.4. Reovirus
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Intratumoral
    • 12.4.2. Intravenous
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Melanoma
    • 12.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 12.5.3. Pancreatic Cancer
    • 12.5.4. Breast Cancer
    • 12.5.5. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By Country/Sub-region

13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2017-2031
    • 13.3.1. Herpes Simplex Virus
    • 13.3.2. Vaccinia Virus
    • 13.3.3. Adenovirus
    • 13.3.4. Reovirus
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Intratumoral
    • 13.4.2. Intravenous
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Melanoma
    • 13.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 13.5.3. Pancreatic Cancer
    • 13.5.4. Breast Cancer
    • 13.5.5. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2017-2031
    • 14.3.1. Herpes Simplex Virus
    • 14.3.2. Vaccinia Virus
    • 14.3.3. Adenovirus
    • 14.3.4. Reovirus
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Intratumoral
    • 14.4.2. Intravenous
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Melanoma
    • 14.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 14.5.3. Pancreatic Cancer
    • 14.5.4. Breast Cancer
    • 14.5.5. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Amgen Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Merck & Co., Inc. (Viralytics Limited)
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. TILT Biotherapeutics
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Oncorus, Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Replimune Group, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Oncolys Biopharma, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Sorrento Therapeutics, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Oncolytics Biotech, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. SillaJen, Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 07: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 11: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 19: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Type, 2022
  • Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2022
  • Figure 04: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Application, 2022
  • Figure 07: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2022
  • Figure 08: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2022
  • Figure 09: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 11: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 12: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 13: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 15: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 16: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2022-2031
  • Figure 17: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country, 2022-2031
  • Figure 21: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 22: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 23: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 24: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 25: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Europe Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 31: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 32: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 33: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 34: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 36: Asia Pacific Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 39: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 40: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 41: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 42: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 43: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Latin America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 48: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 49: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 50: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 51: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 52: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 54: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 58: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 59: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 60: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 61: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031